Business Standard

Serum Institute to seek nod for two full-dose regimen of Covishield

Suresh Jadhav, executive director of the Pune-based firm, said on Friday Serum was seeking approval from the Drug Controller General of India (DCGI) for the two-full dose regimen

Coronavirus, vaccine, covid, drugs, clinical trials
Premium

Trials in India over 1,600 people was done with two-full doses and the data has been submitted to the regulator

Sohini DasReuters Mumbai/London
Serum Institute of India will seek approval for a two full-dose regimen from the Indian drug regulator after its partner, Oxford University, cited data from early trials and said following such a regimen showed a better immune response.

After phase 3 trials, Oxford, which is developing the Covid-19 vaccine Covishield with AstraZeneca, had said a full dose followed by a half-dose regimen showed 90 per cent efficacy, while a full two-dose regimen showed 62 per cent efficacy. However, it had said more work needed to be done to affirm that result.

Suresh Jadhav, executive director of the Pune-based firm, said on Friday

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in